NDC 57664-570 - Amlodipine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 57664-570
- Package NDCs from labels
- 57664-570-99, 57664-570-88, 57664-570-13, 57664-570-18
- Manufacturer
- State of Florida DOH Central Pharmacy
- Effective date
- 2013-08-09
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Amlodipine - State of Florida DOH Central Pharmacy | State of Florida DOH Central Pharmacy | 2013-08-09 | HUMAN PRESCRIPTION DRUG LABEL |
| Amlodipine - CARACO PHARMACEUTICAL LABORATORIES, LTD. | CARACO PHARMACEUTICAL LABORATORIES, LTD. | 2008-12-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 57664-570-13 | Amlodipine | 500 in 1 BOTTLE | TABLET | 500 | 1 | |
| 57664-570-18 | Amlodipine | 1000 in 1 BOTTLE | TABLET | 1000 | 1 | |
| 57664-570-88 | Amlodipine | 100 in 1 BOTTLE | TABLET | 100 | 1 | |
| 57664-570-99 | Amlodipine | 90 in 1 BOTTLE | TABLET | 90 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 57664-570-13 | EA - Each | 57664-570 | 580e2f11-1b48-423e-8de8-93ea0d21237b | 1 | 2013-02-13 |
| 57664-570-18 | EA - Each | 57664-570 | 81a29e57-5a7e-4301-9478-d80acdb8d640 | 1 | 2013-02-13 |
| 57664-570-99 | EA - Each | 57664-570 | da356505-a475-4bfc-a8f2-bc392a32d44e | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Amlodipine and Atorvastatin | AMLODIPINE AND ATORVASTATIN | Alembic Pharmaceuticals Limited | ecab983e-6ed8-4440-b7b4-7ac4bf39b26c | 2025-05-23 | Warnings, Adverse reactions | 864V2Q084H |
| AMLODIPINE, VALSARTAN, HYDROCHLOROTHIAZIDE | AMLODIPINE BESYLATE VALSARTAN HYDROCHLOROTHIAZIDE | Strides Pharma Science Limited | 9b76e441-e6a5-4036-8276-b7788ade5c44 | 2025-04-10 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | A-S Medication Solutions | 921096ab-589a-4821-8d91-a6319f4a559a | 2025-04-09 | Warnings, Adverse reactions | 197361 308136 308135 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | A-S Medication Solutions | dc2107cd-edfa-44a6-b139-edee6ccf47ce | 2025-04-08 | Warnings, Adverse reactions | 308135 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | A-S Medication Solutions | 00a037f6-b17f-4d21-9a9a-0e682f68d483 | 2025-04-02 | Warnings, Adverse reactions | 308136 864V2Q084H |
| Amlodipine and Olmesartan Medoxomil | AMLODIPINE AND OLMESARTAN MEDOXOMIL | Camber Pharmaceuticals, Inc. | 99865c67-5475-4e60-98d5-a8fa850fe9ba | 2025-03-26 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | Aphena Pharma Solutions - Tennessee, LLC | 313fe7ba-2fbd-bb4d-e063-6294a90a3749 | 2025-03-26 | Warnings, Adverse reactions | 197361 864V2Q084H |
| YVTYVT MICRODERMABRASION FACIAL SCRUB | YVTYVT MICRODERMABRASION FACIAL SCRUB | Beijing JUNGE Technology Co., Ltd. | 2f30fc45-42e2-c766-e063-6394a90a8d68 | 2025-02-28 | Warnings | OP1R32D61U |
| Amlodipine and Benazepril Hydrochloride | AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE | A-S Medication Solutions | 1dd12925-ede8-4ad5-9309-d8c79da1cebf | 2025-02-19 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| AMLODIPINE BESYLATE 2.5 mg | AMLODIPINE BESYLATE | Proficient Rx LP | 6313edc5-d2d5-44a1-a06f-7f7829c870d2 | 2025-02-01 | Warnings, Adverse reactions | 197361 308136 308135 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | Redpharm Drug | fc61eee9-ee15-9078-e053-6394a90a22f4 | 2025-01-23 | Warnings, Adverse reactions | 197361 864V2Q084H |
| AMLODIPINE BESYLATE | AMLODIPINE BESYLATE | DIRECT RX | b8b9a3cd-c4e7-dfeb-e053-2a95a90aa719 | 2025-01-17 | Warnings, Adverse reactions | 308136 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | NCS HealthCare of KY, LLC dba Vangard Labs | 47f228e9-4a34-4d14-988d-b06af90124b9 | 2025-01-16 | Warnings, Adverse reactions | 197361 308136 308135 864V2Q084H |
| Amlodipine Besylate and Benazepril Hydrochloride | AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | 7c75fa72-9b0f-44bf-a745-dfa647ed1e78 | 2025-01-15 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| amlodipine,valsartan and hydrochlorothiazide | AMLODIPINE,VALSARTAN AND HYDROCHLOROTHIAZIDE | Macleods Pharmaceuticals Limited | 1ea4f227-b97a-49f1-bbc3-1dede2c1866d | 2025-01-09 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | AMLODIPINE AND OLMESARTAN MEDOXOMIL | Micro Labs Limited | 7fcf6a87-7b3e-4cef-8c47-c8a008cfea82 | 2025-01-09 | Boxed warning, Warnings, Adverse reactions | 864V2Q084H |
| AMLODIPINE BESYLATE 10 mg | AMLODIPINE BESYLATE | Aphena Pharma Solutions - Tennessee, LLC | 1871ddaf-ed2c-c3ce-e063-6394a90a1bee | 2024-12-20 | Warnings, Adverse reactions | 308135 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | Quality Care Products, LLC | a75e4797-6b7f-4366-9105-79d6877adac5 | 2024-12-19 | Warnings, Adverse reactions | 197361 864V2Q084H |
| Amlodipine Besylate | AMLODIPINE BESYLATE | Quality Care Products, LLC | 6b7c18ef-3a85-4ae3-9135-7ac30a0dde08 | 2024-12-17 | Warnings, Adverse reactions | 197361 308135 864V2Q084H |
| amlodipine besylate | AMLODIPINE BESYLATE | Mylan Pharmaceuticals Inc. | 180ee374-24f2-4b9c-9d54-8815f2b1dc9b | 2024-11-28 | Warnings, Adverse reactions | 197361 308136 308135 864V2Q084H |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.